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Summary
Evaluating progression risk and determining optimal therapy for ulcerative colitis (UC) is 
challenging as many patients exhibit incomplete responses to treatment. As part of the PROTECT 
(Predicting Response to Standardized Colitis Therapy) Study, we evaluated the role of the gut 
microbiome in disease course for 405 pediatric, new-onset, treatment-naive UC patients. Patients 
were monitored for one year upon treatment initiation, and microbial taxonomic composition was 
analyzed from fecal samples and rectal biopsies. Depletion of core gut microbes and expansion of 
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bacteria typical of the oral cavity were associated with baseline disease severity. Remission and 
refractory disease were linked to species-specific temporal changes that may be implicative of 
therapy efficacy, and a pronounced increase in microbiome variability was observed prior to 
colectomy. Finally, microbial associations with disease-associated serological markers suggest 
host-microbial interactions in UC. These insights will help improve existing treatments and 
develop therapeutic approaches guiding optimal medical care.
Graphical Abstract:
eTOC blurb:
Many patients exhibit incomplete responses to ulcerative colitis (UC) therapy. Schirmer et al. 
investigate the gut microbiome's role in pediatric UC treated with two conventional therapies. 
Baseline and longitudinal microbial trends are implicated in disease severity and progression, 
including remission and colectomy requirement. These insights may motivate new therapeutic 
approaches.
Introduction
Recent insights into the molecular pathogenesis of inflammatory bowel disease (IBD) 
suggest a complex interplay of susceptibility genes, aberrant mucosal immune responses and 
environmental factors and implicate gut bacteria and their products (Xavier and Podolsky, 
2007). Aberrant immune responses to commensal microbes likely result in lesions of the 
intestinal mucosal layer involving extensive epithelial damage, immune infiltration, crypt 
abscesses, and chronic inflammation – hallmarks of ulcerative colitis (UC). Pediatric UC 
incidence rates are rising, and over 50% of patients present with extensive colitis (Peloquin 
et al., 2016). Converging evidence for genetic- and cell type-specific defects suggest that the 
UC spectrum encompasses multiple disease and immune phenotypes.
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Microbial organisms and products impact immune homeostasis by affecting immune 
education, development and response (Atarashi et al., 2013; Kugathasan et al., 2017; Sartor 
and Wu, 2017; Schirmer et al., 2016; Wlodarska et al., 2015). The IBD gut is characterized 
by reduced microbiome diversity and a depletion of protective bacteria such as short-chain 
fatty acid (SCFA)-producing Ruminococcaceae and Lachnospiracaea (Duvallet et al., 2017; 
Gevers et al., 2014) that coincides with an expansion of pro-inflammatory microbes such as 
Enterobacteriaceae, including Escherichia coli, and Fusobacteriaceae (Gevers et al., 2014; 
Morgan et al., 2012; Shaw et al., 2016). Blooms of Ruminococcus gnavus strains and an 
increase in facultative anaerobes co-occur with more severe IBD activity (Hall et al., 2017). 
Faecalibacterium prausnitzii, a major producer of the SCFA butyrate, displays anti-
inflammatory effects and is reduced in UC patients. In genetically susceptible gnotobiotic 
mice, oral pathobionts such as Klebsiella strains induce T helper 1 cells and elicit severe gut 
inflammation (Atarashi et al., 2017). Microbes also show protective effects in mouse 
models: a mix of 17 Clostridium strains inhibits colitis through induction of regulatory T 
cells (Atarashi et al., 2013), and Bacteroides fragilis mono-colonization protects against 
induced colitis (Chiu et al., 2014). While these studies implicate specific bacteria and 
bacterial products in intestinal health, the IBD microbiome fluctuates more compared to 
healthy controls, highlighting the need for longitudinal sampling of new-onset patients. 
Microbial organisms also impact drug availability and treatment efficacy (Ananthakrishnan 
et al., 2017; Haiser et al., 2013; Sivan et al., 2015; Vetizou et al., 2015). Further, UC is 
pathophysiologically distinct from other types of IBD and may arise from different 
mechanisms. To date, few studies have focused specifically on the UC microbiome.
Current UC therapies inhibit immune system overactivation (Wahl et al., 1998), but little is 
known about their ability to restore gut microbial balance or the impact of the microbiome 
on treatment efficacy. We investigated the microbiome’s role in disease progression during 
the first year of UC therapy as part of the PROTECT (Predicting Response to Standardized 
Colitis Therapy) Study (Hyams et al., 2017). We monitored 405 pediatric, new-onset, 
treatment-naive UC patients (mean age 12.8±3.3 years) upon receiving either 5-ASA 
mesalamine or corticosteroids (CS) followed by mesalamine. Patients refractory to these 
conventional approaches received immunomodulators or anti-TNF biologic therapy as a part 
of a pre-specified treatment algorithm (Fig. S1A). We observed taxonomic shifts prior to 
treatment initiation that were associated with disease severity and progression, including 
remission and colectomy. Analysis of follow-up samples further identified altered microbial 
abundances associated with treatment, temporal changes linked to disease severity and 
increased variability of microbial composition in colectomy patients.
Results
Gut microbiota changes are associated with disease progression
Fecal samples were collected at baseline (week 0, prior to treatment) and 3 follow-up time 
points (4, 12 and 52 weeks after treatment initiation), and paired rectal biopsies were 
collected at baseline and week 52, resulting in a total of 1,212 samples. Extensive clinical 
metadata, including treatment, disease activity and serology, were collected for each patient. 
We analyzed microbial taxonomic composition based on 16S rRNA gene amplicon 
Schirmer et al. Page 4
Cell Host Microbe. Author manuscript; available in PMC 2019 October 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
sequencing to evaluate the role of the gut microbiome in disease progression and treatment 
response.
Treatment initiation improved disease activity and markers of inflammation, such as fecal 
calprotectin levels, for many patients (Fig. 1). Remission was not a consistent outcome 
based on initial disease severity or treatment strategy (Fig. 1A, Fig. S1B). A clear shift in 
taxonomic composition accompanied changes in disease activity and fecal calprotectin 
levels following therapy (Fig. 1B+C). Fecal calprotectin levels increased (Wilcoxon, mild-
inactive p=2*10−16, moderate-mild p=3*10−5, severe-moderate p=3*10−3) with more severe 
disease, and microbial community diversity decreased (Wilcoxon, all p<3*10−3) with 
moderate or severe compared to mild or inactive disease (Fig. 1D, Fig. S1C+D; fecal 
calprotectin (mcg/g): meaninactive=833, meanmild=2003, meanmoderate=2590, 
meansevere=3298). Sample type accounted for some observed variation in community 
composition and was considered as a covariate for all subsequent analyses (Fig. S1E).
Taxonomic composition within patients changed substantially over time, highlighting the 
importance of examining treatment-naive patients to identify relevant early microbial shifts 
(Fig. 1E+F). After 4 weeks, the mean Bray-Curtis distance between samples from the same 
patients was 0.68 (by week 12: 0.69). This further increased to 0.73 by week 52 and was 
comparable to unrelated samples (mean across all time points: 0.81).
Serological markers are implicated in disease progression and associated with microbial 
factors
Serological measurements are commonly used to support IBD diagnosis. Despite high 
specificity, serological biomarkers lack high sensitivity (Peyrin-Biroulet et al., 2007; 
Ruemmele et al., 1998). We measured anti-Saccharomyces cerevisiae antibody (ASCA) 
immunoglobulin A (IgA), ASCA immunoglobulin G (IgG), antineutrophil cytoplasmic 
antibodies (ANCA), anti-flagellin antibodies (CBir1) and anti-outer membrane porin C 
(OmpC) at baseline. ASCA IgA, OmpC and ANCA levels were decreased in patients with 
mild disease (Fig. S1F; Wilcoxon; ASCA IgA: all p<2*10−4, OmpC: all p<0.03, ANCA 
p<10−2), whereas CBir1 was increased (p<0.04). ASCA IgA levels were lower in patients 
who achieved remission without a colectomy, whereas OmpC levels increased in colectomy 
patients. In contrast, baseline ANCA antibodies were increased in patients that achieved CS-
free remission by week 52 (Fig. S1G-J).
We next tested for microbial associations with these biomarkers (FDR<0.2), and those 
associated with disease progression yielded the most associations: ASCA IgA (28 
associations), OmpC (12) and ANCA (8) (Fig. 1G, Table S1). Most ASCA IgA associations 
involved Lachnospiraceae (12 associations) and Ruminococcaceae (5 associations) species, 
including negative correlations with F. prausnitzii and positive correlations with 2 
Veillonellaceae, Megasphaera and Veillonella dispar. The most significant negative 
correlation with OmpC (lowest FDR, see Methods) involved F. prausnitzii and positive 
correlations included 2 Veillonella species (V. dispar and V. parvula). The most significant 
ANCA correlation was a negative association with R. gnavus. Overall, 36 negative and 16 
positive microbial associations with disease-specific changes in antibody levels were 
detected. All but 2 of these operational taxonomic units [OTUs] (Lachnospiraceae and V. 
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dispar) were uniquely associated with a specific antibody, suggesting potential interactions 
between the gut microbiome and the immune system at the antibody level in disease 
progression.
Stool microbial composition overlaps with rectal biopsy profile
We compared paired fecal and rectal biopsy profiles within each patient at baseline to 
determine the extent of community structure overlap (Fig. 2). Although profiles could 
substantially vary for individual patients (Fig. S2A+B), the abundance of each OTU on 
average was comparable in fecal samples and biopsies across patients, with more abundant 
OTUs showing higher correlations (Fig. 2A). Fusobacterium, a known mucin degrader 
(Tailford et al., 2015), showed the largest difference at twice the abundance in biopsies.
IBD microbiomes display a higher degree of intra-individual variability than healthy 
microbiomes (Halfvarson et al., 2017). Our data suggests that dissimilarity increases with 
disease severity (Fig. 2B), however, organisms present in both sample types showed high 
correlation (Fig. S2C). Stool samples generally showed higher diversity than biopsies, even 
though sequencing depth was comparable (Fig. S2D+E). No effect of alpha diversity on the 
stool-biopsy correlation was noticed (Fig. S2F). Overall, sample type accounted for 5.1% of 
the observed variation (Fig. 2C, Fig. S2G). As expected, inter-individual variation accounted 
for most taxonomic variation. Collection week and patient age and gender were also 
significant contributors explaining ~1% of microbiota differences. Disease severity had a 
more substantial effect, accounting for up to 4.5% of variation, and differences in 
community diversity (Chao1) explained as much as 7.8% in baseline stool samples. The 
effect of initial treatment (0.9%) was comparable to the effect of antibiotic usage (1.1%), 
further highlighting the importance of examining treatment-naive samples.
Extensive microbial depletion and expansion of bacteria typical of the oral cavity are 
linked to severe disease in treatment-naive patients
In addition to community-wide shifts, specific OTUs in baseline samples were linked to 
changes in disease severity and progression during the first year after diagnosis (Fig. 3). In 
baseline samples, 50 OTUs were associated with initial disease severity and showed a 
continuous increase or decrease with worsening disease (FDR<0.05). The majority of these 
OTUs (43/50) were depleted in patients with more severe disease and represented 
Ruminococcaceae and Lachnospiraceae (Fig. 3A). Lachnospiraceae were previously 
implicated in IBD, including Clostridium clusters IV and XIVa, which are involved in 
maintenance of gut health and can induce T regulatory cells (Atarashi et al., 2013). 
Considering only rectal biopsies at baseline, 9 significant associations were identified, where 
Streptococcus anginosus was uniquely differentially abundant in biopsies and substantially 
increased in patients with severe compared to mild disease (14-fold).
Strikingly, all OTUs increased in severe disease (V. dispar, Aggregatibacter segnis, 
Campylobacter, Lachnospiraceae, V. parvula, Haemophilus parainfluenzae, Megasphaera) 
represent bacteria typical of the oral cavity (de Vries et al., 2008; Nallabelli et al., 2016; 
Segata et al., 2012). V. dispar, the OTU with the largest decrease between mild and severe 
disease, is implicated in Crohn's disease (CD) (Fig. 3B) (Jacobs et al., 2016). Haemophilus 
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and Veillonella spp. can induce dendritic cell (DC) maturation, which may enable bacteria-
exposed DCs to prime T cell responses (Larsen et al., 2012). H. parainfluenzae was on 
average (mean relative abundance across all samples) the most abundant of the negatively 
implicated oral OTUs (Fig. S3A).
Twenty OTUs were depleted in patients with extensive disease involvement or pancolitis 
compared to patients with proctosigmoiditis or left-sided colitis (Fig. S3B+C). The most 
substantial increased OTUs in extensive or pancolitis, V. parvula and V. dispar, were also 
increased in severe disease at baseline. While disease severity does not necessarily imply the 
extent of disease involvement, our analysis suggests that the microbial signature associated 
with extensive or pancolitis is similar to the signature associated with more severe disease 
(Fig. S3D).
We also predicted metagenomic functional potential based on 16S rRNA profiles. 
Comparing severe and mild disease samples, 126 KEGG pathways were significantly 
increased (n=64) or decreased (n=62) (Table S2). Overall fold-changes (severe/mild) were 
less substantial compared to shifts in taxonomic composition.
Treatment-naive microbiome is linked to refractory and responsive disease
A subset of patients with baseline samples (19/343) progressed to refractory disease and 
required colectomy in the first year after diagnosis (compared to 304 patients with no 
colectomy, 20 unknowns; Fig. S1B). At baseline, 21 OTUs were associated with the later 
requirement of colectomy (Fig. 3C). Among the increased OTUs were 3 oral taxa also 
associated with more severe disease, and 12 of the 17 OTUs decreased in colectomy patients 
were depleted in more severe disease. This suggests that a subset of microbes associated 
with disease severity may be indicative of patients at risk for medically refractory disease.
Depletion of certain microbes at baseline was associated with sustained disease and 
indicative of CS-free remission at weeks 12 and 52 (Fig. 3D+E). Twelve OTUs were 
positively associated with week 12 CS-free remission, including 9 Clostridia and 2 
Erysipelotrichaceae. Commensal Clostridia populate the mucosa in close proximity to 
epithelial cells and play a vital role in maintaining gut barrier function (Pryde et al., 2002). 
Both Erysipelotrichaceae and Clostriales are decreased in treatment-naive CD patients 
(Gevers et al., 2014). Further, 3 Clostridia taxa were positively associated with week 52 CS-
free remission, and 1 was slightly decreased in patients that achieved remission. A decrease 
in Sutterella and an increase in Eggerthella lenta were also positively associated with week 
52 CS-free remission.
Age of disease onset did not play a major role in disease course. We investigated age-related 
differences (patients were 4-17 years old) with regards to remission at weeks 4, 12 and 52, 
colectomy, initial treatment distribution and disease severity. While patients that achieved 
remission at week 12 were significantly younger than patients who did not (Wilcoxon, 
p=0.04), no other comparisons were associated with age of disease onset (all p>0.05).
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Microbes associated with UC severity are antibiotic-responsive
Antibiotics are used to treat septic complications and mild flares in IBD but can substantially 
alter gut microbial community composition and reduce microbial diversity. Many microbes 
associated with antibiotic usage (up to 27 days prior to baseline sample collection; 
FDR<0.2) were implicated in disease severity and progression (Fig. 3A, C-E, Fig. S3E). 
Most OTUs depleted with antibiotic usage were Lachnospiraceae, Ruminococcaceae and 
Clostridiales, including several F. prausnitzii (Fig. S3E). These taxa include many SCFA-
producing bacteria with essential roles in maintaining intestinal epithelial barrier function, 
antimicrobial defense and mucus production (Kelly et al., 2015), suggesting that antibiotics 
may adversely impact the IBD microbiome.
Corticosteroids significantly impact gut microbial composition
Longitudinal analysis showed that initial 5ASA or CS (oral or intravenous [IV]) treatment 
was significantly associated with altered gut microbial abundances (Fig. 4A). We compared 
treatment-naive baseline to week 4 samples grouped by initial treatment and remission 
status. Analysis was restricted to the first follow-up sample as treatment succession was 
highly patient-specific. Initial treatment is likely to exhibit the strongest effect on week 4 
samples as most patients remained on 5ASA or CS during this timeframe. For patients with 
severe disease, IV CS were often followed by oral CS unless escalation to anti-TNF was 
required. In total, 47 OTUs were associated with CS and mostly showed a similar increase or 
decrease in the week 4 CS remission and no remission groups. Opposite trends were 
observed for 2 OTUs (fold changes <1 vs >1). Actinomyces abundance increased in CS-
treated patients that achieved week 4 remission but decreased in those with sustained 
disease. The reverse was observed for a Clostridium OTU. Further, 7 species showed 
significant differences in their mean abundance between the remission and no-remission 
group (Wilcoxon, p<0.05), including 2 Fusobacteria (Table S3). These results notably differ 
from previous cross-sectional analyses involving CS (Morgan et al., 2012), suggesting that 
treatment response may be highly personalized and baseline-sensitive.
With initial 5ASA treatment, 11 OTUs were associated with remission status, all showing 
the same trends in the week 4 remission and no-remission group. Differences (Wilcoxon, 
p<0.05) in abundance with regards to remission status were observed for 5 OTUs, including 
a Fusobacteria implicated in CS treatment efficacy (Table S3).
A decline in gut bacteria typical of the oral cavity over time is linked to improved disease 
severity and potentially favors remission
Trends in associations with disease severity observed in baseline samples persisted in all 
samples longitudinally, however the microbial signature differed. We identified 91 OTUs 
with a continuous increase or decrease across all disease severity categories (inactive, mild, 
moderate and severe; FDR<0.05; Table S4; top 30 associations in Fig. 4B). The most 
significant changes were observed for H. parainfluenzae (FDR=2*10−28) and 
Bifidobacterium (FDR=2*10−27) (Fig. S4A+B). Overall, 32% (29/91) of these OTUs were 
associated with disease severity at baseline (Fig. 3A) and 79% (72/91) were decreased in 
patients with more severe disease.
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In total, 75% (54/72) of OTUs decreased with increasing disease severity were from the 
order Clostridiales, with 24 Lachnospiraceae and 18 Ruminococcaceae, suggesting a 
substantial depletion of SCFA-producing bacteria affecting epithelial barrier function. SCFA 
such as butyrate can inhibit stem cell proliferation (Kaiko et al., 2016), induce tolerogenic 
DCs, increase intestinal regulatory T cell percentages, and elevate intestinal IgA production 
(Goverse et al., 2017). Eight OTUs belonged to the Blautia genus, including many 
Clostridium cluster XIVa species capable of producing butyrate and secondary bile acids 
(Ridlon et al., 2014). Among OTUs with increased abundances in severe disease were 
several oral taxa, including 2 Aggregatibacter, Fusobacterium, 4 Veillonellaceae, 2 
Enterobacteriaceae, 2 Neisseriaceae and H. parainfluenzae. Two Ruminococcus species, R. 
gnavus and R. torques, are human secretory mucin degraders previously observed to be 
increased in IBD (Png et al., 2010).
Temporal changes in H. parainfluenzae further highlighted interesting patterns associated 
with remission (Fig. 4C). Patients with initially severe disease displayed higher levels of H. 
parainfluenzae at baseline that continuously decreased through week 52. This contrasts 
consistent H. parainfluenzae levels in patients with initially mild disease that failed to 
achieve week 52 remission. Decreases in the abundance of certain bacteria, such as H. 
parainfluenzae, may be linked with improved disease outcome.
Comparing the distribution of intra-patient dissimilarity of longitudinal samples revealed a 
greater degree of heterogeneity in colectomy patients (Fig. 4D, Fig. S4C; Wilcoxon; 
p=0.02). All stool samples included in the analysis were collected prior to colectomy. Thus, 
general variability associated with the IBD microbiome is exacerbated in refractory disease 
and may be predictive of patients who will require more extreme interventions.
Discussion
We assessed microbial changes associated with disease progression in a large inception 
cohort of treatment-naive children with new-onset UC. Patients with inactive disease were 
used as a proxy for a control group, and treatment-naive baseline samples served as intra-
patient controls to monitor patient-specific changes over time. A striking increase in bacteria 
typical of the oral cavity in patients with more severe disease was observed at baseline and 
follow-up time points. Healthy guts may be innately resistant to colonization by bacteria 
from the oral cavity; however, inflammation or strain-specific adaptation, including 
antibiotic resistance and virulence genes such as adhesion genes, may allow these microbes 
to colonize the gut mucosa in IBD and exacerbate inflammation. Increased oxygen levels in 
the IBD gut may favor expansion of aerotolerant bacteria from the oral cavity and facilitate 
strain-specific niche adaptation (Atarashi et al., 2017; Hall et al., 2017; Lloyd-Price et al., 
2017). Altered, strain-specific immune responses were previously observed for 
Campylobacter concisus, where IBD strains showed upregulated surface expression of TLR4 
and MD-2 in HT-29 cells (Ismail et al., 2013).
Temporal changes in microbial abundances were correlated with treatment efficacy. In 
particular, H. parainfluenzae was associated with disease severity and remission. 
Interestingly, H. parainfluenzae was detected in biopsies suggesting that it is embedded in 
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the mucosa as an active member of the UC gut. Changes in mucosal microbial communities 
or a defective mucosal barrier may initiate or exacerbate intestinal inflammation. In mouse 
models, a spatial redistribution of bacterial groups in the large intestine was associated with 
inflammation (Swidsinski et al., 2005), and diet-mediated alterations of the gut microbiota 
caused functional mucosal defects that were preventable with the application of B. longum 
or inulin treatment (Schroeder et al., 2018). UC patients with acute inflammation display a 
thin, highly penetrable mucus layer (Johansson et al., 2014; Wlodarska et al., 2015), and 
mucin2 polymorphisms are associated with IBD risk. These findings underscore the 
importance of host-microbial interactions to maintain gut health.
Recent studies identified cross-reactivity between antibodies used as IBD biomarkers and 
bacterial and fungal antigens (Cohavy et al., 2000; Landers et al., 2002). Our analysis, which 
considered serological markers as a continuous variable, revealed several microbial 
associations with specific serological markers, such as OmpC and ASCA IgA. This suggests 
that similar mechanisms may disrupt host-microbial interactions in IBD. OmpC is required 
for adherent-invasive E. coli to thrive in the gut, and anti-OmpC antibodies are associated 
with ileal CD. Positive associations of OmpC with Veillonella and Dorea spp., but not E. 
coli, highlight potential microbial interactions within the changing UC microbiome. ASCA 
IgA targets mannan, a fungal cell wall component that mediates host interactions. Moreover, 
yeast α-mannans serve as nutrients for several Bacteroides species (Cuskin et al., 2015), and 
bacterial-fungal interactions potentially impact the immune response in IBD and impair 
protection against fungal pathogens. Potential cross-reactivity between yeast and bacteria 
remains a subject of future studies.
With current treatment efficacy rates at only 50%, choosing optimal treatment strategies for 
UC remains a challenge. Here, we observed baseline and longitudinal microbial trends 
implicated in progression of UC severity and remission. Although we do not know whether 
these microbial factors are a cause or consequence of UC, they are evidence that the 
microbiome impacts treatment efficacy and may serve as a potential therapeutic resource. 
Microbial biomarkers predictive of disease progression and treatment efficacy could 
transform clinical practices and inform optimal treatment strategies, such as a more 
aggressive treatment regimen for patients at higher risk of progressive disease.
STAR Methods
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to and will be fulfilled by 
Lead Contact Ramnik J. Xavier (xavier@molbio.mgh.harvard.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cohort and sample collection—The PROTECT study consists of 428 new-onset, 
pediatric UC patients recruited between July 2012 and April 2015 from 29 centers in the 
USA and Canada and monitored over the course of one year (Hyams et al., 2017). Patients 
were treatment-naive at baseline (week 0) and assigned one of two conventional treatment 
strategies: (1) 5-aminosalicylic acid (mesalamine) or (2) oral / intravenous (IV) 
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corticosteroids (CS) followed by mesalamine. Treatment strategies were based on disease 
severity and progression (detailed outline in Fig. S1A).
For a subset of 405 patients, stool and rectal samples were collected for microbiome 
profiling. Stool samples were collected at baseline (week 0) and 3 follow-up time points 
(approximately 4, 12 and 52 weeks after initial treatment initiation) in addition to rectal 
biopsies collected at baseline and week 52, resulting in 1,212 samples in total. Metadata and 
clinical data were collected throughout the year, including age, gender, ethnicity, treatment, 
PUCAI, stool consistency, disease progression (colectomy and remission), extent of disease 
involvement, and fecal calprotectin. Subject were between 4 and 17 years of age (mean age 
12.8+/−3.3 years) and 48% (195) were female. Overall, 138 / 136 / 131 patients received IV 
CS / oral CS / 5-aminosalicylic acid (5ASA) as initial treatment at week 0.
Inclusion and exclusion criteria—Eligibility criteria for patients were disease extent 
beyond the rectum (i.e., proctitis excluded), a baseline Pediatric Ulcerative Colitis Activity 
Index (PUCAI) (Turner et al., 2007) score of at least 10, no previous therapy for colitis, and 
stool culture negative for enteric bacterial pathogens (Salmonella, Shigella, Campylobacter, 
Escherichia coli 0157:H7) and Clostridium difficile toxin. A clinical, endoscopic, and 
histological diagnosis of ulcerative colitis was made in accordance with previously 
established criteria (Bousvaros et al., 2007). Patients were followed for a minimum of one 
year and up to three years with no change in diagnosis. None of these patients had 
granulomatous inflammation or small bowel disease other than possible backwash ileitis in 
the presence of cecal disease. Samples were randomized throughout the study, but researcher 
were not blinded with regards to phenotype. No technical replicates were obtained as 16S 
sequencing results have been shown to be highly reproducible within protocol (Sinha et al.). 
All sequencing datasets were required to have at least 3,000 reads after OTU assignment. 
(See details below on data processing.)
Sample number overview
Baseline (week 0) Week 4 Week 12 Week 52
No. of patients 343 243 247 217
No. of biopsies 211 - - 52
No. of stool samples 264 243 247 195
Ethics statement—The PROTECT study was approved by the local investigational 
review boards (IRBs) at each site. Inclusion of volunteers and experiments were conducted 
according to the principles expressed in the Declaration of Helsinki. Written assent was 
obtained for all children before any material was taken.
METHOD DETAILS
Biopsy DNA extraction—Rectal biopsies were obtained at the diagnostic colonoscopy 
and stored in RNALater at −80°C until further processing. Total DNA and RNA were 
isolated using the Qiagen AllPrep RNA/DNA Mini Kit. PolyA-RNA selection, 
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fragmentation, cDNA synthesis, adaptor ligation, and library preparation were performed 
[details on library preparation outlined below; also see (Gevers et al., 2014)].
Stool DNA extraction—Total Nucleic Acid (TNA) was extracted via the Chemagic MSM 
I with the Chemagic DNA Blood Kit-96 from Perkin Elmer, combining chemical and 
mechanical lysis with magnetic bead-based purification. Prior to extraction on the MSM-I, 
TE buffer, Lysozyme, Proteinase K, and RLT Buffer with beta-mercaptoethanol were added 
to each sample. The lysate solution was subsequently vortexed and samples were then 
placed on the MSM I unit. M-PVA Magnetic Beads were added to the lysate solution and 
vortexed. The bead-bound TNA was then removed from solution via a 96-rod magnetic head 
and washed in three ethanol-based wash buffers. The beads were washed in a final water 
wash buffer and dipped in elution buffer to re-suspend the DNA sample in solution. The 
beads were then removed from solution, leaving purified TNA eluate, which was then split 
into two equal volumes (one for DNA, one for RNA). SUPERase-IN solution was added to 
the DNA samples, the reaction was cleaned up using AMPure XP SPRI beads. DNase was 
added to the RNA samples, and the reaction was cleaned up using AMPure XP SPRI beads. 
DNA samples were subsequently quantified using a fluorescence-based PicoGreen assay.
16S rRNA gene sequencing—The V4 variable 16S rRNA region was targeted and 
libraries were sequenced on the Illumina Miseq in paired-end mode (2×175bp). Briefly, 
genomic DNA was amplified using primers designed to incorporate Illumina adapters and 
sample barcodes (Primers: 515F and 806R) (Caporaso et al., 2012). Sample concentration 
was normalized to 1.5ng/μl for stool and 6ng/μl for biopsies. PCR mixtures contained 10 μl 
of sample template, 10 μl of 5PRIME HotMasterMix (Quantabio), and 5 μl of primer mix 
(IDT) at 2 μM concentration of each primer. The cycling conditions consisted of an initial 
denaturation of 94°C for 3 min, followed by 25-30 cycles of denaturation at 94°C for 45s, 
annealing at 50°C for 60s and extension at 72°C for 5 min, and a final extension at 72°C for 
10 min. Amplicons were quantified according to the Caliper LabChip GX: DNA 5K Assay 
(PerkinElmer, Hopkinton, MA), and pooled in equimolar concentrations according to the 
400bp amplicon. The pooled samples were then size selected by Pippin Prep 2% agarose 
protocol (Sage Science, Beverly, MA), removing non-specific amplification products from 
host DNA (375-425 bp). Libraries were sequenced on the Illumina MiSeq v2 platform, 
according to the manufacturer’s specifications with addition of 5% PhiX.
Serology measurements—Serological measurements at baseline were done at Cedars-
Sinai Hospital (Los Angeles, CA, USA) using previously published methods (Dubinsky et 
al., 2008). Briefly, sera were analyzed for expression of anti-Saccharomyces cerevisiae 
antibodies (ASCA) immunoglobulin A (IgA), ASCA immunoglobulin G (IgG), anti-
neutrophil cytoplasmic antibodies (ANCA), anti-flagellin antibodies (CBir1) and anti-outer 
membrane porin C (OmpC) antibodies in a blinded fashion by enzyme-linked 
immunosorbent assay (ELISA). Antibody levels were determined, and results were 
expressed as ELISA units (EU/mL).
Fecal calprotectin—Fecal calprotectin was measured centrally with ELISA (Buhlmann 
Laboratories, Schonenbuch, Switzerland) from stool samples collected around colonoscopy, 
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or at 4, 12, and 52 weeks post diagnosis. Stool samples around colonoscopies were collected 
before colonoscopy cleanout or at least 2 days after colonoscopy, but not more than 3 days 
after initial ulcerative colitis treatment as previously described (Hyams et al., 2017).
Disease severity categories—Patients were grouped into four disease severity 
categories based on their baseline PUCAI score, including inactive (PUCAI: <10), mild 
(PUCAI: 10-30), moderate (PUCAI: 35-60), and severe (PUCAI: ≥65) disease (scores are 
increments of 5).
Remission at week 4/12/52—Clinical remission at week 4 was defined by PUCAI score 
<10 with no prior rescue therapy or colectomy. For remission at week 12 and 52, patients 
were also required to not be on corticosteroid therapy for a minimum of 14 days (for week 
12) and 28 days (for week 52) prior to the assessment time. Rescue therapy included 
immunomodulators, calcineurin inhibitors, and TNF inhibitors.
QUANTIFICATION AND STATISTICAL ANALYSIS
OTU construction and taxonomic assignment—OTU clustering and taxonomic 
profiling of 16 rRNA gene amplicon sequencing data was performed with the 16S bioBakery 
workflow built with AnADAMA2 (McIver et al., 2017), which incorporates ea-utils and the 
UPARSE pipeline (version 8.1). Briefly, paired-end reads from all datasets were first 
merged, filtered and de-replicated. For quality-filtering the UPARSE threshold of Emax=1 
was used, at which the most probable number of base errors per read is zero for filtered 
reads, and a truncation quality threshold of 15. Further reads were trimmed to a fixed length 
of 200bp. OTUs were then sorted by size, singletons were discarded and OTUs were 
clustered at 97% similarity. Subsequently, the representative sequences for each cluster were 
mapped against the Greengenes 16S rDNA database (version 13.5) to filter chimeras and 
obtain taxonomic assignment.
Filtering—All datasets were required to have at least 3,000 reads after OTU assignment. 
Datasets were subsequently normalized for library size and converted to relative abundances. 
Furthermore, OTU were required to occur in at least 20 samples resulting in 1,015 OTUs 
that were used in the downstream analysis. All OTUs, regardless of taxonomic classification 
level, were included for all analyses. Overall, 10% of the OTUs were classified at species, 
44% at genus, 34% at family, 11% at order and less than 1% at class level.
Antibiotics analysis—Antibiotic exposure is relatively common in IBD patients and can 
have long-term, non-linear effects on the gut microbiome. For baseline (week 0) samples the 
recorded antibiotic usage was within 27 days of sample collection for all but one patient 
(334 days; Fig. S2H). For the followup samples we used an omnibus test (permANOVA) to 
determine the treatment window that explains the maximum amount of variation in the 
microbiota in connection with antibiotic exposure (Fig. S2I). A treatment window of 40 days 
was used to encode antibiotics as a binary variable.
Statistical association analysis—Statistical significance was established by boosted 
additive general linear models of OTU abundance as a function of sample metadata using 
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MaAsLin (Morgan et al., 2012). To account for confounding effects, we included several 
covariates in the model. Typical covariates were age, gender, ethnicity and antibiotic usage, 
which were modeled as fixed effects in addition to the respective outcome variable (e.g., 
disease severity). MaAsLin accounts for multiple testing using Benjamini-Hochberg 
correction and the respective FDR values are provided throughout the manuscript. 
Significant associations with antibiotic exposure that overlapped with the outcome variable 
(i.e., disease severity or remission) were indicated in Fig. 3A, 3C and 3D. Furthermore, for 
the longitudinal analysis subject ID was added as a random effect. When stool and biopsy 
samples were analyzed concurrently, sample type was included as well. When evaluating 
remission or remission in connection with initial treatment, disease severity and treatment 
were also taken in account as an additional fixed effect. Treatment was otherwise not 
included in the linear models. Note, that for the association analysis with disease severity 
only OTUs that showed a continuous increase or decrease with increasing disease severity 
were considered (Fig. 3A and 4B).
Gender was taken in account as a covariate for all association analyses. The only significant 
associations (FDR < 0.05) with gender in baseline samples was Parabacteroides distasonis, 
which was increased in female patients (MaAsLin covariates: age, gender, ethnicity, 
antibiotic usage, sample type and PUCAI).
To assess the significance of the difference between averages of groups of samples, a two-
sided Wilcoxon signed-rank test was used (R stats library).
Metabolic pathway predictions—OTU abundances were first normalized by their 
known/predicted 16S copy number prior to predicting metagenomic functional potential 
using the software PICRUSt (Langille et al., 2013). KEGG genes were further summarized 
into metabolic pathways (n=328). All samples were required to have at least 3,000 mapped 
reads and were normalized by library size. Only pathways (n=267) that occurred in at least 
20 samples were subsequently included in the MaAsLin analysis to investigate functional 
differences at baseline comparing mild (nsamples=123) and severe (nsamples=137) disease 
(covariates: sample type, age, gender, ethnicity, antibiotics; random effects: subject ID).
DATA AND SOFTWARE AVAILABILITY
Raw 16S rRNA sequencing data is available through NCBI SRA Bioproject: PRJNA436359. 
The processed OTU table and metadata are available in the supplementary material (Table 
S6).
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Refer to Web version on PubMed Central for supplementary material.
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Highlights:
1. Intestinal microbiome was temporally tracked in new-onset pediatric UC 
patients for 1-year
2. Treatment-naive UC microbiome is associated with disease progression and 
severity
3. Clostridiales depletion and oral pathobiont expansions in the gut link to 
disease course
4. Longitudinal microbial variation link to colectomy need and may impact 
treatment efficacy
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Figure 1: Microbial and serological changes in relation to disease severity and treatment efficacy.
(A) Patients with a baseline (week 0) and at least one follow-up sample were included (week 
0: nsevere=90, nmoderate=139, nmild=75). Ordination analysis (PCoA on Bray-Curtis distance) 
over all samples revealed marked stratification by disease severity (B) and fecal calprotectin 
level (C), which were significantly associated (D; sequential Wilcoxon tests, all p<0.01). 
Stratification closely followed the longitudinal sequence of samples within patients, 
consistent with improvement over time (E). (F) Microbial profiles significantly changed 
(Bray-Curtis) over time within individuals (Wilcoxon; all p<0.05 except for changes from 
week 0-4 to week 0-12). (G) Network of significant associations between microbial clades 
in baseline samples (gray nodes) and serological markers (yellow nodes) determined by 
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linear model coefficients (MaAsLin). Edges summarize the association strength by 
Spearman correlation (red, positive; blue, negative; heavier edge weight implies greater 
strength). See also Fig. S1 and Tables S1+S6.
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Figure 2: Factors associated with variation in microbial community composition.
(A) Comparison of paired microbial profiles in biopsies and stool samples from treatment-
naive patients (n=132, week 0). OTUs were required to occur in ≥20 biopsy or stool samples 
with mean abundance >10−5. Error bars specify SEM, color indicates Spearman correlation 
coefficient for each OTU across all samples. The 15 OTUs with the largest difference 
between sample types (outliers from the x=y line) and the 5 most abundant OTUs (top right) 
are labeled. (B) Intra-patient correlation of biopsy versus stool samples at week 0, stratified 
by disease severity (min. abundance: 10−4). Correlation coefficients decreased with 
increasing disease severity (median Spearman rmild=0.28, rmoderate=0.28, rsevere=0.17), 
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however, this trend was not statistically significant. (C) Microbial taxonomic variation 
explained by various factors (y-axis) for all or only baseline samples (permANOVA, 
nperm=1,999). Percentages indicate variance explained by each variable in single-variable 
models. Total variation explained by all variables is indicated in the final row. See also Fig. 
S2.
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Figure 3: Microbial associations with disease severity, colectomy, and remission.
(A) Significant (FDR<0.05) associations between microbial abundance and disease severity 
in treatment-naive (week 0) stool samples and biopsies (nmild=123, nmoderate=215, 
nsevere=137). Any OTU significantly altered in moderate or severe disease compared to mild 
was included (see also Table S5). Associations are summarized by fold change in mean OTU 
abundance for mild vs. moderate (orange) and mild vs. severe (red) disease. Black 
diamonds/circles indicate OTUs associated with antibiotics. (B) V. dispar was the most 
depleted species in mild disease (Wilcoxon, mild-moderate: p=0.003, moderate-severe: 
p=0.0005). (C) Significant (FDR<0.2) associations between microbial abundance in baseline 
samples and refractory disease requiring colectomy. Associations are summarized by fold 
change in mean OTU abundances in the colectomy group (n=19) vs. patients not requiring 
colectomy (n=304). Significant (FDR<0.2) associations between microbial abundance and 
CS-free remission at week (D) 12 and (E) 52. See also Fig. S3 and Tables S2 and S5.
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Figure 4: Temporal variation in microbial profiles linked to treatment efficacy and disease 
progression.
(A) Microbial changes between week 0 and 4 were associated with initial treatment efficacy 
within each treatment group (CS and 5ASA). Asterisks indicate patient groups for which the 
association was significant (FDR<0.05). (B) Microbial associations with disease severity in 
biopsies and stool samples from all time points (ninactive=447, nmild=337, nmoderate=275, 
nsevere=152). Mean abundances of each disease severity group for the 30 most significant 
OTUs (FDR<10−10). (C) H. parainfluenzae (OTU 865469) levels showed opposing temporal 
trends in connection with CS-free remission at week 52. Patients with initially mild disease 
that failed to achieve remission (dotted grey line) displayed consistent levels, while patients 
with initially severe disease that achieved remission (blue line) showed a substantial 
reduction in H. parainfluenzae. (D) Intra-patient stability was significantly lower (Wilcoxon, 
p=0.02) in the colectomy group. We compared intra-patient similarity of microbial 
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community composition (Bray-Curtis; fecal samples only) from the first 3 time points. 
Dotted lines indicate group medians. See also Fig. S4 and Tables S3+S4.
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